Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candidate into ...

Investing.com - TD Cowen initiated coverage on MBX Biosciences Inc (NASDAQ:MBX) with a Buy rating on Tuesday. The biotech company, currently valued at approximately $922 million, has seen its shares ...

CARMEL, Ind., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

As of November 9, 2025, the average one-year price target for MBX Biosciences is $60.18/share. The forecasts range from a low of $30.30 to a high of $88.20. The average price target represents an ...

$391.7 million in cash, cash equivalents and marketable securities as of September 30, 2025; expected to support operations into 2029 Updated 2026 corporate milestones include clinical data for three ...

MBX Biosciences Inc stock reached a significant milestone, hitting a 52-week high at 26.5 USD. This marks a notable achievement for the company, reflecting a strong performance over the past year.

Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross ...

MBX Biosciences, Inc. (MBX) closed the last trading session at $24.07, gaining 74.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.